|
On (b)(6) 2011 an onxace-23 sn (b)(6) was used in a case for a 57-year-old male patient who underwent aortic valve replacement with root enlargement for bicuspid aortic stenosis.This valve was reported as explanted and replaced in (b)(6) 2026 (approximately 15 years post implant) by another on-x valve.Per the reporting surgeon, the patient presented with pannus formation.A ring of pannus was noted below the valve and pannus above the valve was reported as the likely contributor.The pannus was described as localized to one area.Another on-x valve was implanted at the time of explant.The returned onxace-23 valve (sn (b)(6)) was visually examined following decontamination.Leaflet mobility was confirmed and no device abnormalities were observed.Fibrous tissue consistent with pannus was present at the inflow sewing cuff/inlet flare region.No outflow-side pannus was observed on the returned device, and no pathology or histology was provided.The complaint was confirmed based on observation of pannus-like tissue on the returned device; however, a device defect was not confirmed.The manufacturing records were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.Pannus formation resulted in explant approximately 15 years post implant.The instructions for use (ifu) identify explantation as a risk factor due to adverse events including pannus.The frequency of occurrence for pannus is not established and has been reported for the on-x valve only anecdotally (see, for example, han 2015 for an aortic case and abad 2016 for a tricuspid case).However, bonnichsen et al.Reiterate the claim by vitale et al.That thrombosis and pannus are both present in as many as 45% of cases of obstructed mechanical valves (on-x was not evaluated in this particular study) [bonnichsen 2015, vitale 1997].Pannus formation resulted in explant approximately 15 years post implant.The instructions for use (ifu) identify explantation as a risk factor due to adverse events including pannus.Evaluation of the returned device confirmed the presence of pannus-like tissue; however, no device defect was identified.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to artivion- formerly cryolife/jotec is accurate or has been confirmed by artivion.References: abad c, et al.Dysfunction of an on-x heart valve by pannus.J heart valve dis.2016 sep;25(5):634-637.Bonnichsen cr & pellikka pa.Prosthetic valve thrombus versus pannus ¿ progress with imaging.Circ cardiovasc imaging.2015;8: doi:10.1161/circimaging.115.004283.Han k, et al.Subprosthetic pannus after aortic valve replacement surgery: cardiac ct findings and clinical features.Radiology.2015;276(3):724-731.On-x instructions for use including aortic valve inr 1.5¿2.0 update.Http://www.Onxlti.Com/ifu vitale n, et al.Obstruction of mechanical mitral prostheses: analysis of pathologic findings.Ann thorac surg.1997;63:1101-1106.
|